Cytarabine controlled-release

Drug Profile

Cytarabine controlled-release

Alternative Names: Cytarabine liposomal; Cytarabine sustained-release; DepoCyt; DepoCyte; DepoFoam Encapsulated Cytarabine; DTC 101; NS-101; Savedar

Latest Information Update: 17 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SkyePharma Inc
  • Developer IRCCS San Raffaele; Mundipharma International; Pacira Pharmaceuticals
  • Class Antineoplastics; Arabinonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neoplastic meningitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Carcinomatous meningitis; Lymphomatous meningitis
  • No development reported B cell lymphoma; Neoplastic meningitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 17 Jul 2017 No recent reports on development identified - Phase-II for B-cell lymphoma in Italy (Intrathecal)
  • 17 Jul 2017 No recent reports on development identified - Registered for Lymphomatous meningitis in South Korea (Intrathecal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top